Compare Crispr Therapeutics AG (CRSP) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs AT&T Inc. — how do they compare? Crispr Therapeutics AG trades at $50.56 (market cap $4.97B), while AT&T Inc. trades at $21.52 (market cap $147.86B). The key difference: AT&T Inc. is far larger — about 29.8× Crispr Therapeutics AG's market cap, and AT&T Inc. pays a 5.22% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | T | |
|---|---|---|
Market Cap | $4.97B | $147.86B |
Sector | Health | Media |
52-Week High | $76.78 | $29.62 |
52-Week Low | $44.34 | $20.49 |
Enterprise Value | $3.32B | $293.21B |
Dividend Yield | — | 5.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
AT&T (T) trades at $21.57, up 2.06% today but near 52-week lows amid Starlink competition fears. The stock shows bearish technical signals with RSI at 97.16 suggesting overbought conditions. Fundamentally, T maintains strong profitability with a 16.94% net margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights SpaceX's satellite-to-phone ambitions creating sector-wide pressure, though AT&T continues innovation with 5G drone detection trials.
Despite near-term headwinds, AT&T presents value with a 5.3% dividend yield and low P/E of 7.26. The consensus price target of $26.43 implies 22.6% upside potential. Primary risks include Starlink disruption and telecom sector volatility, but strong cash flow generation and analyst buy ratings (41%) support a constructive long-term outlook for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
